择期外科手术期间国人瑞芬太尼的药物动力学研究

择期外科手术期间国人瑞芬太尼的药物动力学研究

张利萍, 李民^*, 张弨, 张现化

1. 北京大学第三医院麻醉科, 北京 100083;
2. 北京大学第三医院药剂科, 北京 100083

收稿日期:2005-11-18 修回日期:2006-02-10 出版日期:2006-03-15 发布日期:2006-03-15
通讯作者: 李民*

Pharmacokinetics of Remifentanil in Chinese Patients Undergoing Elective Surgery

ZHANG Li-ping, LI Min^*, ZHANG Chao, ZHANG Xian-hua

1.Department of Anesthesiology, Peking University Third Hospital, Beijing 100083, China;
2.Department of Pharmacy, Peking University Third Hospital, Beijing 100083, China

Received:2005-11-18 Revised:2006-02-10 Online:2006-03-15 Published:2006-03-15
Contact: LI Min*

摘要/Abstract

摘要： 目的测定国人全身麻醉下瑞芬太尼的药物代谢动力学参数, 并与既往国外文献进行比较。方法择期手术成年患者10例,在全麻诱导后静脉单次注射瑞芬太尼5 - 6 μg·kg^-1, 随后在注射后0、1、2、3、5、7、10、15、20、25、30、45、60及90分钟抽取动脉血，采用液质联用测定法 (HPLC/MS/MS) 测定瑞芬太尼血药浓度。结果瑞芬太尼血药浓度-时间曲线变化符合二房室模型.平均分布半衰期 (t1/2 α)为1.56 min (0.73~2.31), 消除半衰期 (t1/2β)为 22.07 min (9. 71~36.07), 清除率为 (CL) 2.149 L·min^-1 (1.370~2.629), 表观分布容积(Vd)为 65.766 L (23.069~108.379)。结论国人瑞芬太尼的药代动力学参数中表观分布容积明显大于国外研究结果, 提示不同种族群体间的药代动力学变化存在差异。

关键词: 瑞芬太尼, 瑞芬太尼, 瑞芬太尼, 药代动力学, 药代动力学, 药代动力学, 麻醉, 麻醉, 麻醉, 高效液相分析, 高效液相分析, 高效液相分析, 质谱, 质谱, 质谱

Abstract: Aim To study the pharmacokinetics of remifentanil in Chinese adult patients undergoing elective surgery and compare the results with the data already published. Methods The pharmacokinetics of remifentanil was determined in 10 adult patients undergoing elective surgery. Remifentanil 5 - 6 μg·kg^-1 was administered within 1 min after the induction of anesthesia. One point five millilitre of arterial blood samples were collected at 0 (baseline), 1, 2, 3, 5, 7, 10, 15, 20, 25, 30, 45, 60, and 90 min after drug administration. Remifentanil concentration was assayed by HPLC/MS/MS. Results The concentration-time course of remifentanil was best described by a two-compartment model. Total clearance (CL = 2.149 ± 0.431 L·min^-1) of remifentanil was greater than the normal hepatic blood flow. The distribution half-life (t1/2α) [1.56 ± 0.52 min (0.73 - 2.31)] and the elimination half-life (t1/2β) [22.07 ± 10.30 min (9.71-36.07)] were similar with those in previous reports. Volume of distribution (Vd = 65.766 ± 29.100 L) was about two times greater than that reported in previous studies of other ethnics. Conclusion In the present study, the volume of distribution is significantly greater than that reported in previous studies of other ethnics, indicating that there are some differences in the pharmacokinetics of remifentanil among different ethnics.

Key words: remifentanil, remifentanil, pharmacokinetics, pharmacokinetics, anesthesia, anesthesia, chromatography, chromatography, spectrum analysis, spectrum analysis

中图分类号:

R916.61

R969.1

Supporting: Foundation item: National High-tech Research and Development Program of China (No. 2003AA IZ3413).
^*Corresponding author. Tel.: 86-10-62017691-2548

张利萍, 李民^*, 张弨, 张现化. 择期外科手术期间国人瑞芬太尼的药物动力学研究[J]. .

ZHANG Li-ping, LI Min^*, ZHANG Chao, ZHANG Xian-hua. Pharmacokinetics of Remifentanil in Chinese Patients Undergoing Elective Surgery[J]. .

参考文献

[1] Egan TD, Harry JM, Pierre F, et al. The pharmacokinetics of the new short-acting op ioid remifentanil (GI87084B) in healthy adultmale volunteers [J]. Anesthesiology, 1993, 79: 881-892.
[2] Luis GM, Carl CH. The pharmacokinetics of remifentanil [J]. J Clin Anesthesia, 1996, 8: 679-682.
[3] Egan TD, Huizinga B, Gup ta SK, et al. Remifentanil pharmacokinetics in obese versus lean patients [J]. Anesthesilogy, 1998, 89: 562-573.
[4] Egan TD, Minto CF, Hermann DJ , et al. Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adultmale volunteers [J]. Anesthesiology, 1996, 84: 821-833.
[5] Minto CF, Schneider TW, Egan TD, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development [J]. Anesthesilogy, 1997, 86: 10-23.
[6] Michelsen LG, Holford Nicholas HG, LuW, et al. The pharmacokinetics of remifentanil in patients undergoing coronary artery bypass grafting with cardiopylmonary bypass [J]. Anesth Analg, 2001, 93: 1100-1105.
[7] Selinger K, Lanzo C, Sekut A. Determination of remifentanil in human and dog blood by HPLC with UV detection [J]. J Pharm Biomed Anal, 1994, 12: 243-248.
[8] Zhang C, Zhang LP, Zhang XH, et al. Determination of the concentration of remifentanil in blood by HPLC/MS/MS and its pharmacokinetic characteristics (in preparation).
[9] Westmoreland CL, Hoke JF, Sebel PS, et al. Pharmacokinetics of remifentanil (GI87084B) and its major metabolite (GI90291) in patients undergoing elective inpatient surgery [J]. Anesthesiology, 1993, 79: 893-903.
[10] Minto CF, Schneider TW, Shafer SL. Pharmacokinetics and pharmacodynamics of remifentanil. II. Model application [J]. Anesthesiology, 1997, 86: 24-33.
[11] Egan TD, Kern SE, Muir KT, et al. Remifentanil by bolus injection: a safety, pharmacokinetic, pharmacodynamic, and age effect investigation in human volunteers [J]. Br J Anaesth, 2004, 92: 335-343.
[12] Glass PSA, Hardman O, Kamiyama Y. et al. Preliminary pharmacokinetics and pharmacodynamics of an ultrashort-acting opoid: remifentanil (GI87084B) [J]. Anesth Analg, 1993, 77: 1031-1040.
[13] Egan TD. Remifentanil pharmacokinetics and pharmacodynamics: a preliminary appraisal [J]. Clin Pharmacokinet, 1995, 29: 80-94.
[14] Zhuang XL, Zeng YM, Chen BJ. Modern anesthesiology [M]. 3rd ed. Beijing: People’s Medical Publishing House, 2003, 114.

[1]	杨雁芳, 韦玮, 张雷, 徐嵬, 杨秀伟. UPLC-MS/MS法测定都梁丸中37个成分在大鼠体内的药代动力学[J]. 中国药学(英文版), 2023, 32(7): 560-573.
[2]	饶志, 魏玉辉. 基于三重四级杆质谱仪的一种定向细胞结合的植物化学组分筛选策略:发现中药制剂消癌平注射液中的潜在生物活性成分[J]. 中国药学(英文版), 2023, 32(2): 101-111.
[3]	马雯, 许悦, 王淑园, 李军, 杨宝学. 液相色谱-三重四极杆串联质谱准确定量技术及实验优化研究—以一种新型利尿药为例[J]. 中国药学(英文版), 2022, 31(3): 184-191.
[4]	李晓娇, 栾树鑫, 张洪, 万洪泉, 陈红, 刘成娇, 刘畅, 丁艳华. 单剂量长效利培酮注射液在中国精神分裂症患者体内的药代动力学、药效学和安全性研究[J]. 中国药学(英文版), 2021, 30(3): 206-217.
[5]	周艳, 宋恒文, 邵志超, 尹博民, 付西美, 谢典佑, 韦利军. 一种新的细胞周期蛋白依赖性激酶(CDK)9抑制剂QHRD107对急性髓系白血病的临床前疗效[J]. 中国药学(英文版), 2021, 30(2): 146-156.
[6]	马雯, 宋书香, 李军. 表面辅助激光解吸/离子化质谱技术用于药物和代谢物分析[J]. 中国药学(英文版), 2020, 29(8): 577-590.
[7]	许腾, 王艳, 卢聪, 冯利, 范琳犀, 孙晶, 范蓓, 王琼, 刘新民, 王凤忠. 黄花菜改善模拟微重力所致大鼠抑郁的尿液代谢组学研究[J]. 中国药学(英文版), 2020, 29(3): 176-191.
[8]	徐露露, 尚展鹏, 柴跃, 张扬, 余蓉, 叶敏, 乔雪. 正向×反相离线二维液相色谱-轨道质谱联用检测通脉颗粒中的微量成分[J]. 中国药学(英文版), 2020, 29(11): 793-803.
[9]	杨秀伟, 张友波, 徐嵬. 静脉和灌胃给予大鼠茴香酸对羟基苯乙酯的RP-HPLC法测定和药代动力学研究[J]. 中国药学(英文版), 2020, 29(11): 804-812.
[10]	杨辉, 胡小鹏, 杨晓勇, 刘航, 任亮, 王玮, 刘丽宏, 张小东. 肾移植术后糖皮质激素和他克莫司的药代动力学相互作用[J]. 中国药学(英文版), 2019, 28(4): 257-263.
[11]	刘鑫, 张波, 梅丹, 黄凯. HPLC-MS/MS法测定大鼠血浆中异绿原酸B浓度及其在药代动力学研究中的应用[J]. 中国药学(英文版), 2019, 28(3): 167-173.
[12]	张玲玲, 张慧文, 武世奎, 刘宏, 李静媛, 董馨, 夏慧敏, 王焕芸. UPLC-Q-Exactive-MS 同时测定三臣丸中六种活性成分的药代动力学研究[J]. 中国药学(英文版), 2019, 28(11): 812-824.
[13]	欧阳文鹃, 张亚兰, 徐平声, 戴智勇, 马虹英, 秦群. 国产注射用甲磺酸帕珠沙星在健康人体的药代动力学研究[J]. 中国药学(英文版), 2019, 28(1): 40-48.
[14]	常馨予, 郭桂明, 范峥, 王宏蕾, 刘洋, 韩丽娟. UPLC-MS/MS法测定黄芪桂枝五物汤在大鼠血浆中两种活性成分及药代动力学研究[J]. 中国药学(英文版), 2018, 27(4): 263-272.
[15]	姜华, 杨景明, 曹玲, 贾桂枝, 戴红良, 孟祥才. 高温胁迫对防风药材药代动力学和药效的影响[J]. 中国药学(英文版), 2018, 27(2): 109-115.